After completing her MD PhD at the University of Geneva Medical School, Claire did a postdoctoral fellowship at Harvard University studying key regulators of pancreatic beta cell development and regeneration. In 2010, Claire transitioned to industry joining Merrimack Pharmaceuticals in Cambridge, MA to advance their anti-EGFR program in oncology. In 2013, Claire joined Novartis leading the cross-functional team for Switzerland developing strategic imperatives in development, medical affairs, market access and commercial strategy with a focus on orphan drugs in rare diseases. Bridging her experience in academia and industry, Claire supported biotech and medtech translational projects at the Therapy Development Accelerator of the University of Zurich between 2017 and 2019. Thereafter, Claire joined as Translational Medicine Expert the Autoimmunity, Transplantation & Inflammation Disease Area Unit at NIBR. She is responsible for the design and implementation of Phase 1 and Phase 2 (Proof of Concept) studies in inflammatory diseases.